Sanofi-aventis' obesity drug Acomplia in Swedish reimbursement list
25 April, 2007
Sanofi-aventis has announced that the Swiss Federal Register of Public Health has registered Acomplia (rimonabant) as of May 1, 2007 on the reimbursement list.
Acomplia is reimbursed by the mandatory social security system for the treatment of type 2 diabetic overweight patients (Body Mass Index - BMI - greater than or equal 28 kg/m2) on at least one oral antidiabetic. Acomplia is furthermore reimbursed for the treatment of patients with obesity (BMI greater than or equal 35 kg/m2).
Acomplia will be available at a price similar to those obtained in the countries of the European Union. In Switzerland, Acomplia is indicated in association with a light hypocaloric diet and physical activity for obese patients (Body Mass Index - BMI - greater than or equal to 30 kg/m2) or for overweight patients (BMI greater than or equal to 27 kg/m2) with at least one associated cardiovascular risk factor, when measures taken to reduce weight, such as diet and/or physical activity turned out to be insufficient.
Acomplia is the first member of a new therapeutic class: the CB1 receptor antagonists. The marketing authorisation is based on a thorough analysis of the safety and efficacy results and the assessment of the pivotal clinical trial program of the phase III.
